The trial is currently being conducted on Stem Cell Therapeutics’ (SCT) behalf by Danish drug development company Medicon.
The trial is designed to characterize the pharmacokinetic profile of two currently marketed drugs, identified by SCT as effective in non-clinical models of stroke.
The phase I study subjects will be dosed in two groups staggered by approximately two weeks. The duration of the phase I trial is anticipated to be eight weeks and SCT also has a phase II trial planned to evaluate safety and efficacy of NTx-265 in stroke patients.
“Dosing our first patient represents a turning point in the evolution of Stem Cell Therapeutics from a preclinical R&D company into a company with the capacity to rapidly graduate promising stem cell technologies through clinical safety and efficacy testing in man”, said Dr Alan Moore, chief clinical and regulatory officer of SCT.